Zyversa Therapeutics Stock Today

ZVSA Stock   3.86  0.05  1.28%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 53

 
High
 
Low
Average
ZyVersa Therapeutics is trading at 3.86 as of the 23rd of July 2024, a 1.28% down since the beginning of the trading day. The stock's open price was 3.91. ZyVersa Therapeutics has 53 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for ZyVersa Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of June 2024 and ending today, the 23rd of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
12th of December 2022
Category
Healthcare
Classification
Health Care
ZyVersa Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 834.9 K outstanding shares of which 18.89 K shares are at this time shorted by private and institutional investors with about 0.25 trading days to cover. More on ZyVersa Therapeutics

Moving together with ZyVersa Stock

  0.67TXG 10X Genomics Buyout TrendPairCorr
  0.62VOR Vor BiopharmaPairCorr

Moving against ZyVersa Stock

  0.55IKNA Ikena OncologyPairCorr
  0.54PFE Pfizer Inc Earnings Call This WeekPairCorr

ZyVersa Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Chairman, CoFounderStephen Glover
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities10.9 M10.2 M
Notably Up
Slightly volatile
Non Current Liabilities Total802.7 K844.9 K
Notably Down
Slightly volatile
Total Assets39.2 M22.1 M
Way Up
Slightly volatile
Total Current AssetsM3.4 M
Fairly Down
Slightly volatile
ZyVersa Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ZyVersa Therapeutics' financial leverage. It provides some insight into what part of ZyVersa Therapeutics' total assets is financed by creditors.
Liquidity
ZyVersa Therapeutics currently holds 8.66 K in liabilities. Note, when we think about ZyVersa Therapeutics' use of debt, we should always consider it together with its cash and equity.

Change In Cash

(2.63 Million)
ZyVersa Therapeutics (ZVSA) is traded on NASDAQ Exchange in USA. It is located in 2200 N. Commerce Parkway, Weston, FL, United States, 33326 and employs 7 people. ZyVersa Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.26 M. ZyVersa Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 834.9 K outstanding shares of which 18.89 K shares are at this time shorted by private and institutional investors with about 0.25 trading days to cover. ZyVersa Therapeutics generates negative cash flow from operations
Check ZyVersa Therapeutics Probability Of Bankruptcy
Ownership Allocation
Roughly 98.0 (%) of ZyVersa Therapeutics outstanding shares are held by general public with 0.75 % owned by insiders and only 1.3 percent by institutional investors.
Check ZyVersa Ownership Details

ZyVersa Therapeutics Historical Income Statement

At present, ZyVersa Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Research Development is expected to grow to about 3.4 M, whereas Net Interest Income is forecasted to decline to (51.6 K). View More Fundamentals

ZyVersa Stock Against Markets

ZyVersa Therapeutics Corporate Management

LaBella MSChief RDProfile
Melda OconnellSenior DevelopmentProfile
Pablo MDChief BoardProfile
MD FACCSenior OfficerProfile
Karen CashmereChief OfficerProfile

Already Invested in ZyVersa Therapeutics?

The danger of trading ZyVersa Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ZyVersa Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ZyVersa Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ZyVersa Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

Additional Information and Resources on Investing in ZyVersa Stock

When determining whether ZyVersa Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ZyVersa Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zyversa Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zyversa Therapeutics Stock:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ZyVersa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(958.35)
Return On Assets
(0.12)
Return On Equity
(1.80)
The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.